TxCell move to CMO allows clinical trial to be restarted

Vials
Vials--Courtesy of the University of Michigan CC BY 2.0

TxCell, a French biotech that saw its clinical trial go off the rails when French regulators shut down its clinical manufacturing operation, has restarted the trial after turning production over to a contract manufacturer.

The company said Wednesday that it has received approval from EU regulators to restart its Phase IIb clinical trial with its lead product Ovasave in patients with moderate to severe Crohn’s disease that is resistant to other treatments. Part of the approval was based on the company moving manufacturing to MaSTherCell and the CMO having conducted a series of successful validation runs on the product.

TxCell hired the Belgian CMO last year to take on its clinical supplies and potentially commercial manufacturing for its lead candidate after regulators shut down TxCell’s pilot facility in Besançon, France, in June 2015 over mold issues. At the time the plant was closed, TxCell said it expected to make improvements and reopen its facility, but after a new CEO took over, it decided to go the CMO route.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Since then, the company has picked contract manufacturer PCT to handle its clinical supply manufacturing in the U.S.

- here’s the announcement

Related Articles:
CMO helps TxCell move forward with clinical supplies after pilot plant closed
Contract manufacturer PCT will handle TxCell production in U.S.
TxCell halts drug production, a decision made with French regulator



 

 

 

Read more on

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.